1 day Ago By ABMN Staff
Virtu Financial LLC decreased its holdings in SELLAS Life Sciences Group, Inc. ( NASDAQ:SLS – Free Report ) by 48.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC.
The fund owned 41,155 shares of the company’s stock after selling 38,086 shares during the quarter. Virtu Financial LLC’s holdings in SELLAS Life Sciences Group were worth $43,000 at the end of the most recent quarter. A number of other institutional investors have also recently made changes to their positions in the stock.
XTX Topco Ltd bought a new stake in SELLAS Life Sciences Group during the third quarter valued at approximately $78,000. State Street Corp grew its position in shares of SELLAS Life Sciences Group by 30.2% during the 3rd quarter.
State Street Corp now owns 174,529 shares of the company’s stock valued at $218,000 after acquiring an additional 40,500 shares during the period. Opus Capital Group LLC increased its stake in shares of SELLAS Life Sciences Group by 5.5% in the 4th quarter.
Opus Capital Group LLC now owns 238,500 shares of the company’s stock worth $248,000 after purchasing an additional 12,400 shares in the last quarter. Brooklyn FI LLC bought a new position in SELLAS Life Sciences Group in the 4th quarter worth $677,000. Finally, Geode Capital Management LLC lifted its position in SELLAS Life Sciences Group by 17.
1% during the third quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock valued at $757,000 after purchasing an additional 88,183 shares in the last quarter. Hedge funds and other institutional investors own 17.
38% of the company’s stock. SELLAS Life Sciences Group Trading Up 0.9 % SELLAS Life Sciences Group stock opened at $1.
09 on Wednesday. SELLAS Life Sciences Group, Inc. has a 12-month low of $0.
77 and a 12-month high of $1.84. The firm has a market capitalization of $99.
02 million, a price-to-earnings ratio of -1.58 and a beta of 2.43.
The firm has a 50 day moving average of $1.23 and a 200 day moving average of $1.17.
About SELLAS Life Sciences Group ( Free Report ) SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. Read More Want to see what other hedge funds are holding SLS? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for SELLAS Life Sciences Group, Inc. ( NASDAQ:SLS – Free Report ). Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.
com's FREE daily email newsletter ..
_8.jpg?itok=wp-xhXRB)
